DACOMITINIB

DACOMITINIB

Biochem/physiol Actions

Dacomitinib (PF-00299804) is an irreversible EGFR inhibitor and antineoplastic. It is a potent inhibitor of HER-1 (EGFR), -2 and -4 tyrosine kinase with IC50s of 6.0, 45.7 and 73.7 nM respectively for EGFR, ERBB2 and ERBB4. Dacomitinib is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3573762 DACOMITINIB white to beige 100 SIGMA-ALDRICH room temp
£502.82 (exc VAT) per 25MG
-
+
3573763 DACOMITINIB white to beige 100 SIGMA-ALDRICH room temp
£140.68 (exc VAT) per 5MG
-
+